ORAL COMMUNICATION | Semaglutide plus empagliflozin improves renal outcomes compared with monotherapies in type 2 diabetes: a real-world study. Ital J Med [Internet]. 2026 May 22 [cited 2026 May 22];20(s1). Available from: https://www.italjmed.org/ijm/article/view/2593